Gilatide

Drug Profile

Gilatide

Latest Information Update: 08 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Thomas Jefferson Medical College
  • Developer Thomas Jefferson Medical College; TorreyPines Therapeutics Inc
  • Class Nootropics; Peptides
  • Mechanism of Action Cyclic AMP response element-binding protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Mild cognitive impairment

Most Recent Events

  • 08 Apr 2005 Discontinued - Preclinical for Mild cognitive impairment in USA (unspecified route)
  • 20 Apr 2001 Axonyx has acquired exclusive rights to gilatide
  • 30 Nov 2000 Preclinical development for Mild cognitive impairment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top